November 2004
Gut;Nov2004, Vol. 53 Issue 11, p1722
Academic Journal
Correction Notice
Several corrections to the articles including "Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor antibody treatment," by S. J. Connor, "Morphological characterisation of Crohn's disease fistulae," by F. Bataille, and "Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001," by G. Masala that were published in the previous issues are presented.


Related Articles

  • Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients. Ohama, Takashi; Hori, Masatoshi; Fujisawa, Masahiko; Kiyosue, Masaharu; Hashimoto, Masaki; Ikenoue, Yuka; Jinno, Yoshio; Miwa, Hiroto; Matsumoto, Takayuki; Murata, Takahisa; Ozaki, Hiroshi // Journal of Gastroenterology;2008, Vol. 43 Issue 11, p858 

    Chronic intestinal inflammation is frequently accompanied by motility disorders. We previously reported that proinflammatory cytokines, such as tumor necrosis factor α and interleukin (IL)-1β downregulate CPI-17, an endogenous inhibitor of serine/threonine protein phosphatase in...

  • Recent Approaches in Pathogenesis of Inflammatory Bowel Disease. Solanki, Roshni; Madat, Dhaval; Chauhan, Khushbu; Parmar, Lalkrushn // International Journal of PharmTech Research;Jul-Sep2010, Vol. 2 Issue 3, p1796 

    Inflammatory bowel disease (IBD) commonly refers to ulcerative colitis (UC) and Crohn disease (CD), which are chronic inflammatory diseases of the GI tract of unknown etiology. This inflammatory response is most likely made possible by defects in both the mucosal immune system and the barrier...

  • Suppression of interleukin-1ß- and tumor necrosis factor-·-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. Andoh, Akira; Ogawa, Atsuhiro; Kitamura, Ken-ichi; Inatomi, Osamu; Fujino, Sanae; Tsujikawa, Tomoyuki; Sasaki, Masaya; Mitsuyama, Keiichi; Fujiyama, Yoshihide // Journal of Gastroenterology;2004, Vol. 39 Issue 12, p1150 

    Background. To elucidate the molecular mechanisms involved in the therapeutic effects of leukocytapheresis (LCAP), we investigated the alterations in the cytokine responses of peripheral blood mononuclear cells (PBMCs) before and after LCAP therapy in ulcerative colitis (UC) patients....

  • Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Balding, Joanna; Livingstone, Wendy J.; Conroy, Judith; Mynett-Johnson, Lesley; Weir, Donald G.; Mahmud, Nasir; Smith, Owen P. // Mediators of Inflammation;Jun2004, Vol. 13 Issue 3, p181 

    T he mechanisms responsible for development of inflammatory bowel disease (IBD) have not been fully elucidated, although the main cause of disease pathology is attributed to up-regulated inflammatory processes. The aim of this study was to investigate frequencies of polymorphisms in genes...

  • The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice. Rieder, Florian; Siegmund, Britta; Bundschuh, Daniela S.; Lehr, Hans-Anton; Endres, Stefan; Eigler, Andreas // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Objective: The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis. We examined the effect of roflumilast, a selective PDE4 inhibitor marketed for severe COPD, and the...

  • Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Blair, Stephanie A.; Kane, Sunanda V.; Clayburgh, Daniel R.; Turner, Jerrold R. // Laboratory Investigation (00236837);Feb2006, Vol. 86 Issue 2, p191 

    The intestinal epithelial barrier is frequently disrupted in inflammatory bowel disease (IBD) and this has been proposed to play a role in disease pathogenesis and reactivation. In vitro studies show that cytokine-induced epithelial barrier dysfunction can be mediated by increased myosin light...

  • Innovations in IBD treatment. Cope, Graham // Gastrointestinal Nursing;Apr2015, Vol. 13 Issue 3, p6 

    The author expresses his thoughts on some of the technological innovations in treatment of inflammatory bowel diseases (IBD). Topics include the impact of anti-tumour necrotizing factor (TNF)-alpha agents on IBD treatment, the overall goals in the management of patients with IBD, and the key...

  • JournalScan.  // Gut;Oct2005, Vol. 54 Issue 10, p1480 

    The article presents information on several articles published in this journal. The article "Infliximab As Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study" explains the pattern of cytokine activation in Crohn's and ulcerative colitis (UC)....

  • Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment. Deleporte, Amélie; Viennot, Stéphanie; Dupont, Benoît; Gilletta, Cyrielle; Allaire, Manon; Prévost, Frédérique; Reimund, Jean-Marie // International Journal of Interferon, Cytokine & Mediator Researc;2013, Vol. 5, p11 

    Pathogenesis of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), continues to drive basic research to better decrypt their causal factor(s). Several key mediators involved in IBD pathogenesis have been identified and are considered as potential...


Read the Article


Sign out of this library

Other Topics